CELL INTELLIGENCE · 肿瘤细胞治疗研究

BACKGROUND: The clinical benefits of cluster of differentiation 30 (CD30)-target chimeric antigen receptor T-cell (CAR-T) therapy in patients with lymphoma remain controversial. This meta-analysis intended to comprehensively investigate the efficacy and safety of CD30-targeted CAR-T therapy in these patients. METHODS: Studies on CD30-targeted CAR-T therapy for patients with lymphoma were searched comprehensively in Web of Science, PubMed, Embase, and Cochrane Library databases until March 2025. A single-arm meta-analysis was performed to calculate pooled proportions with 95% confidence intervals (CI). Heterogeneity was assessed using the I statistic, and fixed- or random-effects models were applied accordingly. Efficacy and safety outcomes were extracted and analyzed. RESULTS: A total of seven studies containing 102 cases were included in this meta-analysis. The pooled rates (95% CI) of complete response, partial response, stable disease, and progressive disease were 43.5% (17.6%; 69.3%), 17.5% (3.0%; 31.9%), 17.8% (3.0%; 32.6%), 10.7% (4.8%; 16.6%), respectively. The pooled objective response rate (95% CI) and disease control rate (95% CI) were 66.1% (46.4%; 85.9%) and 89.3% (83.4%; 95.2%). Regarding safety results, the pooled incidences (95% CI) of cytokine release syndrome, nausea or vomiting, anemia, and thrombocytopenia were 57.7% (37.7%; 77.8%), 38.2% (11.3%; 65.1%), 79.1% (48.0%; 100.0%), and 70.2% (36.1%; 100.0%), respectively. No publication bias was observed in any outcome measures (all P > 0.05). Quality assessment showed that all included studies were of moderate-to-high quality. Moreover, sensitivity analyses exhibited high robustness of results. CONCLUSION: CD30-targeted CAR-T therapy demonstrates promising objective response rates with manageable toxicities in patients with lymphoma. The findings of this meta-analysis provide preliminary descriptive evidence to inform future clinical research and exploratory application of CD30-targeted CAR-T therapy in lymphoma.